Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Solara Active Pharma Sciences has announced an investor conference call on May 15, 2026, at 3:00 PM IST to discuss its audited financial results for Q4 FY26. This call will provide an opportunity for analysts and investors to engage with management regarding the company's performance.
May 11 2026 16:05:00
Solara Active Pharma Sciences Ltd - 541540 - Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 ('Listing Regulations')
Solara Active Pharma Sciences will hold a board meeting on May 15, 2026. The agenda includes considering and approving the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
May 08 2026 21:05:00
Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Solara Active Pharma Sciences successfully closed the US FDA inspection for its Puducherry manufacturing facility. The inspection was classified as Voluntary Action Indicated (VAI), ensuring continued cGMP compliance for the Ibuprofen plant.
Apr 28 2026 17:04:00
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences announced the successful closure of its Puducherry facility's US FDA inspection, which was classified as 'Voluntary Action Indicated (VAI)'. This outcome demonstrates the company's commitment to quality and regulatory compliance for its Ibuprofen manufacturing unit.
Apr 28 2026 17:04:00
Read More